Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Announces 33% Staff Cut, Will Focus Internally On Two Lead RNAi Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

The RNA interference pioneer will focus on two candidates, ALN-TTR02 for transthyretin-mediated amyloidosis and ALN-APC for hemophilia, while seeking partners for its other “5x15” programs.

You may also be interested in...



Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results

The RNA interference-focused biotech will bring the rest of its pipeline forward with subcutaneous technology now that it has been validated in human studies, but the company will continue to pursue approval of its lead candidate as an infusion product.

Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn

Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.

Genzyme’s Asian Expertise Drives Alnylan Co-Development Pact For TTR Candidates

RNAi pioneer Alnylan is partnering its transthyretin-mediated amyloidosis program with Genzyme in Japan and Asia-Pacific, while planning to keep rest-of-world rights to the program in-house.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel